Today marked a milestone moment for Sironax. We celebrated recent transformative achievements – the strategic expansion of our US team and IND approvals from China CDE. These are pivotal steps that position us to accelerate global development while staying root-ed in groundbreaking science.
At Sironax, we tackle the hardest problems in degenerative diseases. We are deeply proud of our team’s relentless pursuit of innovation, having successfully advanced several FIC/BIC candidates into clinical development. Standing at this turning point, we’re closer than ever to a future where once-inevitable diseases are no longer a threat, and disease-modifying ther-apies transform lives of millions of patients and their families.
“The future is not written—it is ours to create.”
With a strengthened global footprint and a pipeline of FIC/BIC assets, we’re poised to rede-fine what’s possible.
About Sironax
Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic and rare diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with NAMPT activator SIR4156, SARM1 inhibitor SIR2501, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups.